NAVIGATOR
Tezepelumab in Severe, Uncontrolled Asthma
Doente / População Intervenção / Exposição Comparação Desfecho
In 1,061 patients with severe uncontrolled asthma, tezepelumab 210 mg SC every 4 weeks reduced the annualised asthma exacerbation rate compared with placebo.
N
1061
Desenho
Multicentre phase-3 RCT
Desfecho
Annualised asthma exacerbation rate
Relevância
2
Resultado0.93 vs 2.10 (RR 0.44; 95% CI 0.37–0.53); benefit preserved in eosinophils <300/µL (RR 0.59).
Menzies-Gow A, et al. N Engl J Med. 2021;384(19):1800-1809. 10.1056/NEJMoa2034975
Discussão e crítica
First biologic effective across all asthma phenotypes — including low-eosinophil disease; FDA-approved 2021.